Ipamorelin: Benefits, Dosage, the CJC-1295 Stack, and Cost
Medically reviewed by the Rite Aid Health Team · Last updated June 16, 2026
Ipamorelin is a selective growth-hormone secretagogue — a pentapeptide that triggers a clean pulse of growth hormone with minimal effect on cortisol, prolactin, or appetite.
That selectivity is why it is favored over older secretagogues, and why it is almost always paired with CJC-1295 to produce a stronger, more sustained GH release.
It is used for recovery, body composition, and sleep. IGF-1 is the blood marker that tracks its effect. If you're comparing GH-axis peptides, start with our peptide therapy guide.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide — a chain of five amino acids — classified as a growth-hormone secretagogue. It is an agonist of the ghrelin receptor (the GH-secretagogue receptor), the same receptor the body's hunger hormone acts on.
Activating that receptor triggers the pituitary to release growth hormone. What sets ipamorelin apart from earlier secretagogues is its selectivity: it stimulates GH release without meaningfully raising cortisol, prolactin, or appetite.
Benefits and uses
Ipamorelin's benefits follow from the GH pulse it triggers:
- Recovery. Growth hormone drives tissue repair, so ipamorelin is used to support recovery from training.
- Body composition. Higher GH and IGF-1 support lean mass and fat metabolism.
- Sleep quality. GH is released in deep sleep, and users commonly report improved sleep on ipamorelin.
- Cleaner profile than older secretagogues. Because it spares cortisol and prolactin and doesn't spike appetite, it produces the GH benefit without the side effects that limited earlier compounds.
How it works
Ipamorelin binds the ghrelin/GH-secretagogue receptor on the pituitary and triggers a pulse of growth hormone. That GH then drives the liver to produce IGF-1, which carries out most of GH's tissue effects.
Because it works through the secretagogue receptor — a different system from the GHRH receptor that sermorelin and CJC-1295 act on — ipamorelin and a GHRH analog can be combined to recruit both pathways at once, which produces a larger and more sustained GH release than either alone.
Dosage and administration
Ipamorelin is given by subcutaneous injection, commonly dosed at night and/or before training to align with natural GH release. It is most often run alongside CJC-1295 rather than on its own. Exact dosing is set by the prescribing provider; there is no FDA-approved ipamorelin product.
Reconstitution (mixing the lyophilized powder with bacteriostatic water) and drawing the right volume on an insulin syringe is where most people make errors.
Use the peptide dosage calculator to convert your target dose into syringe units for your vial size.
Side effects and safety
Ipamorelin's selectivity gives it a favorable side-effect profile relative to older secretagogues — it does not spike cortisol, prolactin, or appetite.
Reported effects are generally mild: injection-site reactions, headache, flushing, or transient lightheadedness. As with any GH-axis therapy, monitor IGF-1 to keep GH activity in a safe range, and work with a provider. Long-term human safety data is limited.
Cost and how to get ipamorelin
Cost depends on the pharmacy, the dose, and whether it is run with CJC-1295, and is set at the point of prescription — we do not publish a price here.
The cleanest route is a prescription filled by a licensed compounding pharmacy after an evaluation that includes baseline blood work. Products sold online "for research use only" are not quality-controlled for human use and carry both quality and legal risk.
Rite Aid is preparing compounded peptide consultations. Join the waitlist to claim 20% off your first ipamorelin order when consultations and ordering open.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
Ipamorelin and CJC-1295 — why they're stacked
Ipamorelin is almost always run with CJC-1295, and the reason is mechanical. Ipamorelin is a secretagogue acting on the ghrelin receptor; CJC-1295 is a GHRH analog acting on the GHRH receptor.
Triggering both receptors at once produces a larger, more sustained GH pulse than either does alone — the secretagogue amplifies the pulse while the GHRH analog extends it.
Sermorelin is the GHRH analog used where a shorter-acting signal is preferred, and MK-677 is the oral secretagogue alternative. For stack comparisons, see how muscle and performance peptides are combined.
Blood work to track ipamorelin
Ipamorelin's purpose is to raise growth hormone, so the blood work confirms whether it's working and keeps it in a safe range:
- IGF-1 — the primary readout. IGF-1 reflects average GH activity and should rise if ipamorelin is working. This is the single most useful test.
- Human growth hormone — a direct GH measurement to complement IGF-1.
- Bodybuilder's hormone test — broader hormonal context for those running a GH-axis cycle for body composition.
Test at baseline before you start and again at 4–8 weeks to confirm IGF-1 has moved.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
FAQ
Recovery, body composition, and sleep — all driven by triggering a clean pulse of the body's own growth hormone. It is favored for doing so without raising cortisol, prolactin, or appetite.
They act on different receptors — ipamorelin on the ghrelin/secretagogue receptor, CJC-1295 on the GHRH receptor. Triggering both at once produces a larger, more sustained GH pulse than either alone.
By subcutaneous injection, commonly at night and/or before training, usually alongside CJC-1295. There is no FDA-approved product or official dosing; dosing is set by the prescribing provider.
Generally mild — injection-site reactions, headache, flushing, lightheadedness. Its selectivity means it avoids the cortisol, prolactin, and appetite effects of older secretagogues. Long-term human safety data is limited.
IGF-1 is the marker that confirms it. Test at baseline and again at 4–8 weeks; IGF-1 should rise if the peptide is doing its job.
Sleep and recovery changes are often reported within the first weeks. Body-composition changes typically need 8–12 weeks, though IGF-1 can shift within the first month.